Essex Financial Services Inc. lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 25.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,662 shares of the medical instruments supplier’s stock after buying an additional 538 shares during the period. Essex Financial Services Inc.’s holdings in Becton, Dickinson and Company were worth $604,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in BDX. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB grew its holdings in shares of Becton, Dickinson and Company by 13.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock worth $39,951,000 after purchasing an additional 20,859 shares during the period. Arete Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $767,000. Busey Bank raised its holdings in Becton, Dickinson and Company by 3.8% in the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock valued at $15,031,000 after buying an additional 2,399 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after buying an additional 1,317,723 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.
Insider Activity
In other Becton, Dickinson and Company news, Director Jeffrey William Henderson bought 1,500 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were purchased at an average price of $233.62 per share, with a total value of $350,430.00. Following the completion of the acquisition, the director now directly owns 8,015 shares of the company’s stock, valued at $1,872,464.30. This represents a 23.02 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 700 shares of the firm’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the sale, the director now owns 36,033 shares in the company, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,544 shares of company stock worth $2,370,309. 0.36% of the stock is currently owned by company insiders.
Becton, Dickinson and Company Trading Down 1.7 %
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities research analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.
Becton, Dickinson and Company announced that its Board of Directors has authorized a stock repurchase program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.84%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.
Analyst Upgrades and Downgrades
BDX has been the subject of a number of recent analyst reports. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Buy” and a consensus price target of $283.00.
Get Our Latest Stock Report on BDX
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- How to Read Stock Charts for Beginners
- Inflation Persists, But So Do Stock Opportunities: Rally On
- What is the Dow Jones Industrial Average (DJIA)?
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.